Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients

J Geriatr Oncol. 2020 May;11(4):724-726. doi: 10.1016/j.jgo.2019.07.002. Epub 2019 Aug 8.

¹ Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America.
² Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States of America; Cancer Biostatistics Shared Resource, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America.
³ Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, United States of America.
⁴ Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, United States of America.
⁵ Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, United States of America. Electronic address: [email protected].
⁶ Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States of America. Electronic address: [email protected].

No abstract available

Keywords: Elderly; IMDC; Immune checkpoint inhibitor; Metastatic renal cell carcinoma; Older patients; Tyrosine-kinase inhibitor.

Publication types